Published in Oncology on January 01, 2002
The utility of conventional and molecular pathology in managing breast cancer. Breast Cancer Res (2008) 0.76
Cardiotoxicity with adjuvant trastuzumab use in breast cancer: A single institution's experience. J Saudi Heart Assoc (2010) 0.75
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res (2008) 6.63
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res (2008) 5.88
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med (2009) 3.86
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol (2006) 2.84
Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol (2012) 2.50
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin Oncol (2013) 2.26
CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest (2013) 2.18
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther (2013) 1.90
What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncol (2004) 1.89
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol (2011) 1.85
18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med (2013) 1.82
Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev (2013) 1.82
DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol Med (2011) 1.81
HER2-positive circulating tumor cells in breast cancer. PLoS One (2011) 1.73
Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One (2011) 1.72
Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics (2008) 1.71
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol (2005) 1.66
Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol (2013) 1.59
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res (2006) 1.58
Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. Lancet Oncol (2005) 1.48
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer (2013) 1.43
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer (2007) 1.31
The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BMC Med Genomics (2009) 1.19
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer (2013) 1.17
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther (2004) 1.17
A fuzzy gene expression-based computational approach improves breast cancer prognostication. Genome Biol (2010) 1.16
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer (2013) 1.11
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst (2013) 1.10
The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. Crit Rev Oncol Hematol (2006) 1.10
A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol (2012) 1.08
The future of breast cancer research in danger. Eur J Cancer (2002) 1.08
Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Mol Cancer Ther (2006) 1.07
Progress and new standards of care in the management of HER-2 positive breast cancer. Eur J Cancer (2007) 1.06
Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol (2002) 1.06
Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics (2009) 1.05
HER-2 as a target for breast cancer therapy. Clin Cancer Res (2009) 1.04
Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment. Clin Cancer Res (2012) 1.03
Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther (2006) 1.03
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2. Breast Cancer Res Treat (2013) 0.99
Beyond trastuzumab: new treatment options for HER2-positive breast cancer. Breast (2011) 0.98
Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol (2004) 0.98
Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist (2010) 0.97
Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagn Mol Pathol (2009) 0.97
Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients. Int J Cancer (2006) 0.97
The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer (2010) 0.95
Molecular forecasting of breast cancer: time to move forward with clinical testing. J Clin Oncol (2006) 0.94
The biological features and prognosis of breast cancer diagnosed during pregnancy: a case-control study. Acta Oncol (2011) 0.93
Personalized therapy for breast cancer: a dream or a reality? Future Oncol (2013) 0.93
A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Res Treat (2014) 0.90
Neoadjuvant therapy for breast cancer. Annu Rev Med (2014) 0.90
Reducing the global breast cancer burden: the importance of patterns of care research. Clin Breast Cancer (2005) 0.89
What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur J Cancer (2006) 0.89
Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology. BMC Genomics (2014) 0.88
A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. Crit Rev Oncol Hematol (2006) 0.88
International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Res (2014) 0.86
Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer . Am Soc Clin Oncol Educ Book (2013) 0.85
Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS). PLoS One (2010) 0.85
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat (2012) 0.84
Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis. PLoS One (2013) 0.83
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. Curr Med Res Opin (2013) 0.82
RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res (2015) 0.81
Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors. Invest New Drugs (2008) 0.81
Breast cancer gene expression profiling: clinical trial and practice implications. Pharmacogenomics (2005) 0.81
Use of trastuzumab for the treatment of early stage breast cancer. Expert Rev Anticancer Ther (2006) 0.81
Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer. PLoS One (2013) 0.80
Gene profiling assay and application: the predictive role in primary therapy. J Natl Cancer Inst Monogr (2011) 0.80
Adjuvant therapy in elderly patients with breast cancer. Clin Breast Cancer (2004) 0.77
New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective. Expert Rev Anticancer Ther (2004) 0.77
Are we HER-ting for innovation in neoadjuvant breast cancer trial design? Breast Cancer Res (2009) 0.77
Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium. Pharmacoeconomics (2002) 0.76
Trastuzumab and breast cancer. Are we just beyond the prologue of a fascinating story? Onkologie (2005) 0.75
Expert roundtable: emerging questions in ErbB2-positive breast cancer; February 22, 2007. Clin Breast Cancer (2008) 0.75
Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nat Commun (2017) 0.75
[Has the time arrived for gene expression use at the bedside?]. Bull Cancer (2008) 0.75
Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. Clin Cancer Res (2002) 0.75
[Kidney cancer: from biology to clinical medicine]. Rev Med Suisse (2006) 0.75
Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP). J Chemother (2013) 0.75